Veraxa Biotech CFO reports zero VRXA holdings

Veraxa Biotech AG - Post de-SPAC (VRXA) has a new Section 16 reporting person: Chief Financial Officer Willener Raju Sudir filed an initial statement of beneficial ownership on Form 3.

Rhea-AI Filing Summary

Veraxa Biotech AG - Post de-SPAC (VRXA) has a new Section 16 reporting person: Chief Financial Officer Willener Raju Sudir filed an initial statement of beneficial ownership on Form 3. The filing reports no transactions and does not list any reportable holdings or derivative positions at this time.

Key Figures

Buy transactions: 0 Sell transactions: 0 Net insider shares bought or sold: 0 shares +1 more

4 metrics

Buy transactions 0 Number of insider purchase transactions reported in the Form 3

Sell transactions 0 Number of insider sale transactions reported in the Form 3

Net insider shares bought or sold 0 shares Net buy/sell shares from the transaction summary

Reported holdings entries 0 Number of non-derivative or derivative holding lines reported

Key Terms

Form 3, beneficial ownership, Chief Financial Officer, Section 16

4 terms

Form 3 regulatory

"filed an initial statement of beneficial ownership on Form 3"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficial ownership regulatory

"serves as his initial statement of beneficial ownership as a Section 16"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Chief Financial Officer financial

"reporting person, Willener Raju Sudir, is the Chief Financial Officer"

A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.

Section 16 regulatory

"as a new Section 16 reporting person of Veraxa Biotech AG"

Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filing for VRXA by Willener Raju Sudir disclose?

The Form 3 for VRXA by Chief Financial Officer Willener Raju Sudir reports no transactions, no reportable share holdings, and no derivative positions. It serves as his initial statement of beneficial ownership as a Section 16 reporting person of Veraxa Biotech AG.

Does the VRXA Form 3 show any shares owned by the chief financial officer?

No. The Form 3 for VRXA indicates zero reportable holdings of common stock or derivatives for Chief Financial Officer Willener Raju Sudir as of the filing, and the transaction summary shows no buys, sells, or other equity transactions.

Are there any insider buy or sell transactions reported in this VRXA Form 3?

No. The Form 3 transaction summary for VRXA shows 0 buy transactions, 0 sell transactions, and 0 net shares bought or sold. This filing only establishes the insider’s reporting status without recording any trades.

What role does the reporting person hold at Veraxa Biotech AG (VRXA)?

The reporting person, Willener Raju Sudir, is identified as the Chief Financial Officer of Veraxa Biotech AG. As an officer, he is required to file reports of beneficial ownership of VRXA equity securities under Section 16 rules.

Does the VRXA Form 3 mention any Rule 10b5-1 trading plan?

No. The Form 3’s Rule 10b5-1 indicator is null, and there are no transactions or footnotes describing any pre-arranged Rule 10b5-1 trading plan for the reporting person in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 04:10 PM Accepted by SEC EDGAR 09/14/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Willener Raju Sudir

(Last) (First) (Middle)

TALACKER 35

(Street)

ZURICH V8 8001

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
09/01/2026

3. Issuer Name and Ticker or Trading Symbol
Veraxa Biotech AG - Post de-SPAC [ VRXA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Raju Willener	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)